1 / 8

RNAi Therapeutics Market

The global RNAi therapeutics market was valued at USD 11.20 billion in 2022 and is expected to reach USD 20.23 billion in 2030, with a CAGR of 7.69% during the forecast period 2023-2030.

sonali58
Download Presentation

RNAi Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RNAi Therapeutics Market

  2. RNA interference (RNAi) is an established biological reaction to double-stranded RNA that provides resistance to both endogenous parasite and external pathogenic nucleic acids while also regulating protein-coding gene expression. RNA therapeutics is a fast-increasing class of pharmaceuticals that will accelerate treatments to the clinic, enable customized therapy, and render the label "undruggable" obsolete. • RNAi therapeutics is used as it consists of a new class of drug molecules. Three types of RNA interference molecules are often distinguished: short hairpin RNAs (shRNAs), microRNAs (miRNAs), and small interfering RNAs (siRNAs). A wide range of diseases, such as oncology, cardiovascular diseases, respiratory disorders, kidney diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and more are cured by using RNAi therapeutics. Download Sample PDF

  3. Market Drivers The substantial growth in the RNAi therapeutics market is strongly influenced by heightened research and development efforts aimed at addressing chronic diseases. 1 The increasing collaboration activities between drug distribution companies and Contract Research Organizations (CROs) contribute to the growth of the RNAi therapeutics market. 2 2 2

  4. On the basis of application, the sub-markets include genetic disorders, oncology, neurodegenerative disorders, infectious diseases, renal diseases, and others. • On the basis of type, the sub-markets include small interfering RNA (siRNA), and microRNA (miRNA). Market Segmentation 1 2 3 • On the basis of route of administration, the sub-markets include intradermal injections, pulmonary delivery, and intravenous injections. 4 • On the basis of end user, the sub-markets include diagnostic laboratories, research and academic laboratories, and hospitals.

  5. Segmentation by Region

  6. Leading Market Players • Alnylam Pharmaceuticals, Inc. • QIAGEN • Olix Pharmaceuticals, Inc. • Arbutus Biopharma • Silence Therapeutics • Dicerna Pharmaceuticals, Inc. • Arrowhead Pharmaceuticals, Inc. • Phio Pharmaceuticals • Quark Software Inc. • Benitec Biopharma Limited

  7. 2nd Floor, Ganadish Empire, Contact: Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027 Call Us: +91 99239 50043  Mail: info@infiniumglobalresearch.com Web: www.infiniumglobalresearch.com

  8. Thank You!!

More Related